Beta Thalassemia Testing Market Key Companies Profile and SWOT Analysis by 2031

MARKET INTRODUCTION

Beta thalassemia is a diseased state of blood in which there is a reduced hemoglobin production. Hemoglobin is a protein containing iron and is present in Red blood cells, and the primary function of hemoglobin is to carry oxygen to the body cells throughout the body. Low hemoglobin content in beta-thalassemia patients usually leads to the lack of oxygen in many parts of the body. Due to the shortage of blood in the body patient, skin becomes pale yellow, and the other symptoms like weakness and fatigue are prominent. The risk of abnormal blood clotting highly persists in the patients suffering from beta-thalassemia. Beta thalassemia testing helps in the diagnosis of beta-thalassemia, thereby reducing morbidity and mortality rates.

MARKET DYNAMICS

The beta thalassemia testing market has shown a significant evolution over the forecast period. The rising incidence of beta thalassemia majorly drives the rise of the beta thalassemia testing market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world. Increasing pipeline drugs in beta thalassemia is expected to drive the growth of the market. There are about 15 pipeline products under clinical trials for the treatment of beta thalassemia. For instance, in December 2016, Kiadis Pharma announced Phase I/II clinical trial with ATIR201 for thalassemia. Moreover, the offering of prenatal testing and the use of advanced molecular testing is expected to create lucrative opportunities for the new players entering the beta thalassemia testing market. However, stringent regulatory policies and high treatment costs are likely to restrain the market growth.

MARKET SCOPE

The "Beta Thalassemia Testing Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry's medical device, with a specific focus on the global market trend analysis. This report outlines the beta thalassemia testing market with detailed market segmentation by technology, treatment, and end-user. The beta thalassemia testing market is estimated to witness a high rise during the forecast period. It focuses on the vital statistics on the leading players' market status in the beta thalassemia testing market and provides key opportunities and trends in the market.

MARKET SEGMENTATION

The market is categorized based on the technology, treatment, and end user. Based on the technology, the market is segmented as perinatal testing, complete blood count (CBC), DNA testing, and others. Based on the treatment, the segmentation of the market is into blood transfusion, iron chelation therapy, folic acid supplements, and others. Based on end user, the segmentation of the market is into hospitals and clinics, diagnostic centers, and others.

REGIONAL FRAMEWORK

The report states a detailed outline of the industry, consisting of both quantitative and qualitative information. It offers a sketch and forecast of the beta thalassemia testing market based on various segments. The report also consists of market size and forecast estimates from the year 2021 to2031with respect to five main regions, namely; North America, Asia-Pacific (APAC), Europe, Middle East, and Africa (MEA), and South & Central America (SCAM). The beta thalassemia testing market by each region is then sub-segmented into respective countries and segments. It comprises the analysis and forecast of 18 countries globally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the beta thalassemia testing market from both the demand and supply sides. Furthermore, it evaluates market dynamics regarding the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. It also consists of precise PEST analysis for all five regions, namely, North America, Asia Pacific, Europe, Middle East and Africa, and South & Central America, after assessing political, social, economic, and technological factors affecting the Beta thalassemia testing market in these regions.

MARKET PLAYERS

The report contains critical developments in the beta thalassemia testing market as inorganic and organic growth strategies. Several companies are pivoting on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed were collaborations and acquisitions &partnerships. Various such activities have paved the path for elaborating the business and customer base of market players. The market players from the beta thalassemia testing market are estimated to have profitable growth opportunities in the coming years with the higher demand for beta thalassemia testing in the global market. Given below is the list of a few companies engaged in the beta thalassemia testing market.
The report also offers key players' profiles in the beta thalassemia testing market, along with their SWOT analysis and market strategies. Also, the report focuses on the key market players with information on company profiles, financial information of the last three years, components, and services provided, critical development in the past five years.

•  Trinity Biotech Plc.
  
•  Bio-Rad Laboratories, Inc.
  
•  Thermo Fisher Scientific Inc.
  
•  PerkinElmer Inc.
  
•  Chromsystems Instruments & Chemicals GmbH.
  
•  BioMedomics, Inc.
  
•  CapitalBio Technology Inc.
  
•  Randox Laboratories Ltd.
  
•  EKF Diagnostics Holdings plc
  
•  Fujirebio
  

The Insight Partner's dedicated research and the analytical team comprises of experienced professionals with advanced statistical expertise and offers several customization options in the current report.

Beta Thalassemia Testing Report Scope